High‐dose posaconazole for azole‐resistant aspergillosis and other difficult‐to‐treat mould infections

Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)

(2019) Jon Salmanton-García et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Posaconazole-Induced Pseudohyperaldosteronism

(2018) Kevin Kuriakose et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease

(2017) Oliver A Cornely et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations

(2017) Katharine E. Stott et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs

(2017) Jochem B Buil et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Toxicity of Vincristine Combined With Posaconazole in Children With Acute Lymphoblastic Leukemia

(2017) Esra Pekpak et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

The global problem of antifungal resistance: prevalence, mechanisms, and management

(2017) David S Perlin et al.   LANCET INFECTIOUS DISEASES

Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation

(2017) Tyler K Liebenstein et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

(2016) Thomas F. Patterson et al.   CLINICAL INFECTIOUS DISEASES

PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay ® in 201 patients with haematological disease suspected for invasive aspergillosis

(2016) G. M. Chong et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

(2016) Johan A Maertens et al.   LANCET

Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species

(2015) Anuradha Chowdhary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multicenter Evaluation of MIC Distributions for Epidemiologic Cutoff Value Definition To Detect Amphotericin B, Posaconazole, and Itraconazole Resistance among the Most Clinically Relevant Species of Mucorales

(2015) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus

(2015) Paul E. Verweij et al.   DRUG RESISTANCE UPDATES

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease

(2015) Oliver A. Cornely et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and Mucormycosis

(2014) Russell E. Lewis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside

(2014) Seyedmojtaba Seyedmousavi et al.   DRUG RESISTANCE UPDATES

Molecular characterization andin vitroantifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India

(2014) Anuradha Chowdhary et al.   MYCOSES

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

(2013) H. R. Ashbee et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Posaconazole Pharmacodynamic Target Determination against Wild-Type andCyp51Mutant Isolates of Aspergillus fumigatus in anIn VivoModel of Invasive Pulmonary Aspergillosis

(2012) Alexander J. Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers

(2012) G. Krishna et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Triazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in Aspergillus fumigatus

(2012) Eveline Snelders et al.   PLoS One

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

(2011) Paul Hamberg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma

(2010) S H Jang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility

(2010) E. Spreghini et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene

(2009) E. Mavridou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Outcome and Medical Costs of Patients with Invasive Aspergillosis and Acute Myelogenous Leukemia–Myelodysplastic Syndrome Treated with Intensive Chemotherapy: An Observational Study

(2008) Lennert Slobbe et al.   CLINICAL INFECTIOUS DISEASES

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES